Collaborations and consortia
We join with institutions and scientists the world over to address foundational challenges in science and health.
All of Us is gathering and analyzing health data from one million or more people living in the United States.
AVE is propelling systematic measurement of variant impact on functional elements of human and pathogen genomes.
BRaVa is a collaborative effort between 16 biobanks and cohorts from across the globe to analyse rare genetic variation.
The NCI- and NHGRI-funded TCGA molecularly characterized over 20,000 primary cancer and matched normal samples spanning 33 cancer types.
CISID takes on ambitious questions in infectious disease research to broadly transform the diagnosis, treatment, and management of infection.
An international consortium studying the genetic determinants of COVID-19 susceptibility, severity, and outcomes.
The DMC brings the Broad Institute and industry partners to work together to create resources to accelerate the pace of precision cancer medicine.
This nationwide research network aims to accelerate the incorporation of genetic and other risk information into clinical care.
The NHGRI-funded ENCODE Consortium is building a comprehensive parts list of functional elements in the human genome.
A policy-framing and technical standards-setting organization, GA4GH seeks to enable responsible genomic data sharing.
GBMI is creating a framework to jumpstart global collaboration among biobanks and similar initiatives.
GIANT seeks to identify genetic loci that modulate human body size and shape.
gnomAD aggregates and harmonizes exome and genome sequencing data from population-scale sequencing projects.
GTEx is developing a resource for studying gene expression and regulation and its relationship to genetic variation.
The HCA is creating cellular reference maps for every cell type in the human body.
The ICDA aims to accelerate discovery from genetic maps to biological mechanisms to physiology and medicine.
IGVF is developing a framework for understanding the effects of genomic variation on genome function and phenotypes.
The Joint Undertaking in Morphological Profiling (JUMP)-Cell Painting Consortium created a new imaging data-driven approach to drug discovery.
The Ladders to Cures (L2C) Scientific Accelerator catalyzes advances leading to treatments and cures for patients with genetically-defined diseases.
OASIS is assessing the combination of Cell Painting, transcriptomics and proteomics in a variety of cell models for drug compound safety assessment.
PGC advances genetic discovery of biologically, clinically, and therapeutically meaningful insights in psychiatry.
Sentinel is an early warning outbreak framework to detect pathogenic threats in real-time and prepare the global community to stop diseases before they spread.
This NHLBI-funded program is exploring the fundamental biological processes that underlie heart, lung, blood, and sleep disorders and advancing precision medicine.
